A University of Melbourne & Texas Medical Center backed Australian Precision Medicine software company trading since 2012. Aim: Fast-Track finding the right antidepressant with genetics. CNSDose - our US$140 cutting edge RCT evidence backed blood-brain-barrier pharmacogenetic powered report boosts antidepressant remission rates. Start a conversation with your doctor... A large fully independent randomized controlled trial to confirm clinical utility in complex depression starts recruiting in 2021. If positive, CNSDose may well be declared the gold standard in the segment globally. Watch this space. CNSDose partners with exclusive lab distributors globally, our cloud platform turns 50 gene variants into a simple medication guidance report. We're interoperable with most genotyping arrays and lab information system platforms. Email our founder direct (a practicing psychiatrist) on aprofsingh@gmail.com to explore commercial opportunities.